Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)41

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)22

Views

Views
November 20240
December 20241
January 20250
February 20252
March 202516
April 20253
May 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States3
United Kingdom2
Spain1
 

Top cities views

Views
Council Bluffs1